Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report
- PMID: 32880812
- DOI: 10.1007/s12328-020-01216-2
Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report
Erratum in
-
Correction to: Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report.Clin J Gastroenterol. 2021 Apr;14(2):696. doi: 10.1007/s12328-020-01246-w. Clin J Gastroenterol. 2021. PMID: 32978712 No abstract available.
Abstract
Mesalazine formulations are essential for treating ulcerative colitis (UC), and intolerance to these formulations complicates the treatment of this condition. Some cases of mesalazine formulation intolerance are caused by the excipients rather than the active ingredient mesalazine. Therefore, mesalazine administration can be continued in such cases by changing the mesalazine formulation. This report describes a case of intolerance to mesalazine in which UC was effectively treated by switching mesalazine formulations. A drug-induced lymphocyte stimulation test suggested that allergy to the additive povidone was the cause of mesalazine formulation intolerance. This is the first case study to identify an additive that caused mesalazine formulation intolerance.
Keywords: Drug-induced lymphocyte stimulation test; Excipient; Mesalazine formulation intolerance; Ulcerative colitis.
Similar articles
-
Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.Clin J Gastroenterol. 2016 Oct;9(5):302-5. doi: 10.1007/s12328-016-0675-2. Epub 2016 Aug 8. Clin J Gastroenterol. 2016. PMID: 27503129
-
Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.Scand J Gastroenterol. 2015 Apr;50(4):399-405. doi: 10.3109/00365521.2014.962608. Epub 2015 Jan 29. Scand J Gastroenterol. 2015. PMID: 25633468 Clinical Trial.
-
[Two cases of drug-induced intrathoracic lesions caused by mesalazine in patients with ulcerative colitis].Nihon Kokyuki Gakkai Zasshi. 2011 Jul;49(7):538-42. Nihon Kokyuki Gakkai Zasshi. 2011. PMID: 21842693 Japanese.
-
Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.Aliment Pharmacol Ther. 2007 Nov 1;26(9):1179-86. doi: 10.1111/j.1365-2036.2007.03471.x. Aliment Pharmacol Ther. 2007. PMID: 17944732 Review.
-
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:37-40. doi: 10.1111/j.1365-2036.2006.03058.x. Aliment Pharmacol Ther. 2006. PMID: 16961743 Review.
Cited by
-
Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis.Digestion. 2023;104(1):58-65. doi: 10.1159/000527452. Epub 2022 Nov 10. Digestion. 2023. PMID: 36366816 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical